Key Points
Guardant Health, Inc. (GH) moved lower today, slipping from a previous close of $108.52 to $102.54. The stock finished down 5.51%, declining $5.98 on the session. The pullback trimmed recent gains and added to a choppy week of trading for the NASDAQ-listed Health Care name.
Trading activity skewed lighter than usual, with below-average volume accompanying the decline. From a technical perspective, shares now sit about 9% below the 52-week high of $112.43 set on 11/25/2025, keeping the stock in a consolidating range after a strong multi-month advance. The prior closing area near $108–$109 may act as initial resistance if bids return, while the psychologically important $100 level is the first area of near-term support that traders will monitor.
Recent sessions have featured quick rotations across Health Care, with selective risk-taking giving way to intraday reversals. That backdrop can magnify moves in higher-beta growth profiles such as GH, especially when liquidity is thinner. With broader market tone mixed and momentum names digesting outsized year-to-date gains, today’s slide fits a pattern of profit-taking and range-trading rather than a break in the longer-term trend. Sector flows and macro rate expectations remain key near-term drivers for the group.
Why Guardant Health, Inc. Price is Moving
At $102.54, GH carries a market capitalization of $13.98 billion. The company remains unprofitable on a trailing basis, with EPS (TTM) at $-3.21. Over the past year, shares have traded between $29.91 and $112.43, underscoring elevated volatility as investors weigh rapid growth against ongoing losses. Today’s move occurred on below-average volume, suggesting a technically driven session dominated by momentum and positioning rather than heavy fundamental re-pricing.
On the fundamentals, top-line expansion remains notable. Reported quarterly revenue rose to $265.20 million for the period ended 09/30/2025 from $232.09 million for the quarter ended 06/30/2025, a sequential increase of 14.3%. From a news and flows perspective, the available record does not identify a single definitive catalyst for today’s 5.5% drop. However, several recent developments provide context: an insider sale disclosed on Dec. 1 (Terilyn Monroe selling 55,167 shares at $105.97 for $5.85 million) and an upsized public offering that closed on Nov. 7, 2025, which can revive dilution concerns during periods of consolidation. Meanwhile, analyst sentiment is constructive on ratings, but an average price target near $80.86—below current levels—signals valuation caution despite growth.
Putting these elements together, the decline appears consistent with profit-taking after a substantial year-to-date rally and sensitivity to valuation in a risk-on/risk-off tape. GH’s negative earnings profile, double-digit price-to-sales multiple, and rapid ascent have left the stock vulnerable to pullbacks when buyers step back. In the Health Care Equipment and Services industry, investor attention remains focused on sustainable margin improvement and cash flow progress, both of which are key to validating the recent revenue trajectory and supporting the current market cap.
What is the Guardant Health, Inc. Rating - Should I Sell or Buy?
Weiss Ratings assigns GH a D rating. Current recommendation is Sell.
The rating is built on five indices: the Good Growth Index (reflecting robust revenue expansion, consistent with reported 38.50% growth), the Very Weak Efficiency Index (highlighting operational inefficiency and persistent losses, in line with a -44.18% profit margin and a negative -33.78 P/E ratio), the Fair Solvency Index (indicating an adequate, but not strong, balance sheet), the Fair Total Return Index (suggesting middling risk-adjusted performance across timeframes), and the Weak Volatility Index (pointing to elevated price swings and downside risk). Together, these indexes indicate that while top-line growth is present, execution and risk factors weigh heavily on risk-adjusted prospects.
Against sector peers HUM (D+), DXCM (D+), and CNC (D), GH sits in a similarly challenged cohort. The group reflects a market that is rewarding selective growth but discounting operational efficiency and stability. GH’s stronger growth profile does not translate into superior risk-adjusted returns versus peers when volatility and profitability are incorporated.
This D rating signals that, in our view, the stock’s overall risk/reward is unfavorable at present. Growth alone isn’t sufficient to offset Very Weak efficiency, negative earnings, and elevated volatility. The Fair readings for solvency and total return help, but they do not overcome the combined drag from profitability and risk. Within the Weiss framework, these elements synthesize into a Sell recommendation, emphasizing that the path to a better rating would require sustained margin improvement, clearer progress toward profitability, and a more stable trading profile.
About Guardant Health, Inc.
Guardant Health, Inc. operates in the Health Care sector within the Health Care Equipment and Services industry, focusing on precision oncology. The company develops and commercializes blood-based tests that analyze circulating tumor DNA (ctDNA) to inform cancer screening, detection, therapy selection, and disease monitoring. Founded in 2012 and headquartered in Redwood City, California, Guardant leverages next-generation sequencing and advanced bioinformatics to deliver clinically actionable insights from a simple blood draw.
The company’s portfolio includes clinical tests such as Guardant360 and Guardant360 CDx for comprehensive genomic profiling in advanced solid tumors, helping physicians match patients to targeted therapies without requiring invasive tissue biopsies. Guardant Reveal addresses minimal residual disease detection to support adjuvant treatment decisions and surveillance in earlier-stage cancers. In screening, the Shield blood test targets colorectal cancer detection as a less invasive alternative to traditional methods. Guardant also serves biopharmaceutical partners with companion diagnostics development, clinical trial testing, and real-world data services that support drug development and regulatory submissions.
Guardant’s competitive position reflects early leadership in liquid biopsy, a broad installed base of ordering physicians, and an expanding body of clinical evidence. FDA approvals for companion diagnostics, payer coverage arrangements, and partnerships with leading oncology centers enhance adoption. The company’s proprietary sequencing chemistry, analytics pipeline, and large-scale datasets are core differentiators that improve sensitivity and specificity over time. Strategic priorities typically center on expanding indications, improving test performance and turnaround times, and deepening biopharma collaborations, all aimed at increasing clinical utility and integrating blood-based testing across the continuum of cancer care.
Investor Outlook
For GH, investors should watch whether the $100 area holds as support and how quickly shares can reclaim the $108–$110 zone, alongside volume trends that confirm or fade momentum. With a Weiss D (Sell) rating, the focus remains on improving efficiency, narrowing losses, and sustaining revenue growth to shift the risk/reward profile. See full rankings of all D-rated Health Care stocks inside the Weiss Stock Screener.